探索含有烯胺的环胺作为LSD1抑制剂:设计,合成,ADMET,MD分析和抗癌活性分析
Khursheed Ahmad Sheikh1, Darakhshan Parveen1, M Mumtaz Alam1
1Drug Design and Medicinal Chemistry Lab, Department of Pharmaceutical Chemistry, School of Pharmaceutical Education & Research, Jamia Hamdard, New Delhi 110062, India.
Bioorganic chemistry
|April 18, 2024
概括
研究人员设计了具有抗癌性能的新皮里米丁衍生物. 三种化合物 (VIIb,VIIi,VIIm) 对各种癌细胞系表现出强烈的抗癌活性,并抑制了LSD1,提供了有前途的治疗途径.
科学领域:
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
- 癌症生物学 癌症生物学
背景情况:
- 皮里米丁衍生物正在探索其治疗潜力.
- 基于结构的设计对于开发有针对性的抗癌剂至关重要.
- 氨酸特异性去甲基酶1 (LSD1) 是癌症治疗中验证的标.
研究的目的:
- 设计,合成和评估新型含有环烯胺的烯胺衍生物的抗癌活性.
- 研究这些化合物的结构-活性关系 (SAR).
- 评估它们作为LSD1抑制剂的潜力.
主要方法:
- 基于结构的设计和合成十八种κυανωπυριμιδίνη衍生物.
- 对ADMET特性 (吸收,分布,新陈代谢,分泌,毒性) 的计算预测.
- 在体外抗癌活性查使用硫胺B测定对抗60个癌细胞系和正常的HEK-293细胞.
- 在体外LSD1抑制试验.
主要成果:
- 大多数化合物表现出有利的ADMET配置文件,包括良好的溶解性,高GI吸收率,并且没有变异原体风险.
- 化合物VIIb,VIIi和VIIm显示出对多个癌症细胞系的显著功效.
- 这些强效化合物还显示出强烈的LSD1抑制活性,IC50值在1.80至6.08μM之间.
- 特定的结构特征,如n-propyl-thio/isopropyl-thio组和替代的环,增强了抗癌活性,特别是对抗白血病的异基.
结论:
- 开发的胺衍生物代表了有前途的抗癌药物,具有作为LSD1抑制剂的潜力.
- 该研究确定了增强抗癌疗效的关键结构决定因素.
- 这些发现为进一步优化新型癌症疗法提供了坚实的基础.
相关概念视频
Structure-Activity Relationships and Drug Design
710
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
710
Preparation of 1° Amines: Hofmann and Curtius Rearrangement Overview
3.2K
In the presence of an aqueous base and a halogen, primary amides can lose the carbonyl (as carbon dioxide) and undergo rearrangement to form primary amines. This reaction, called the Hofmann rearrangement, can produce primary amines (aryl and alkyl) in high yields without contamination by secondary and tertiary amines.
3.2K
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
3.0K
Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
3.0K
Physical Properties of Amines
3.1K
Amines with low molecular weight are usually gaseous at room temperature, while those with high molecular weight are liquid or solids in nature. Usually, low molecular weight amines have a rotten fish-like smell. Diamines typically have a pungent smell. For instance, cadaverine and putrescine, depicted in Figure 1, are two molecules responsible for decaying tissue.
3.1K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
160
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
160

![Solid-phase Synthesis of [4.4] Spirocyclic Oximes](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F58508.jpg&w=3840&q=50)
